Renaissance Technologies LLC Has $19.86 Million Stock Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Renaissance Technologies LLC raised its stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 174.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,108,616 shares of the biopharmaceutical company's stock after buying an additional 1,339,316 shares during the period. Renaissance Technologies LLC owned approximately 0.71% of Amicus Therapeutics worth $19,863,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. R Squared Ltd acquired a new position in shares of Amicus Therapeutics during the 4th quarter worth approximately $79,000. Virtu Financial LLC acquired a new position in Amicus Therapeutics in the 3rd quarter valued at $107,000. KBC Group NV boosted its holdings in shares of Amicus Therapeutics by 44.4% during the fourth quarter. KBC Group NV now owns 10,154 shares of the biopharmaceutical company's stock worth $96,000 after purchasing an additional 3,120 shares during the last quarter. Sciencast Management LP acquired a new position in Amicus Therapeutics in the fourth quarter valued at $100,000. Finally, Stephens Inc. AR acquired a new position in shares of Amicus Therapeutics during the 4th quarter valued at about $101,000.

Amicus Therapeutics Trading Up 1.9 %

FOLD stock traded up $0.13 during mid-day trading on Friday, reaching $6.83. 3,105,452 shares of the stock traded hands, compared to its average volume of 2,606,205. The stock's fifty day moving average is $8.48 and its 200-day moving average is $9.55. The company has a market cap of $2.10 billion, a P/E ratio of -37.94, a P/E/G ratio of 1.51 and a beta of 0.79. The company has a current ratio of 3.39, a quick ratio of 2.42 and a debt-to-equity ratio of 2.01. Amicus Therapeutics, Inc. has a 52-week low of $6.20 and a 52-week high of $12.65.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on FOLD shares. Cantor Fitzgerald restated an "overweight" rating and issued a $21.00 price target on shares of Amicus Therapeutics in a report on Wednesday, January 15th. Wells Fargo & Company reduced their price objective on Amicus Therapeutics from $18.00 to $17.00 and set an "overweight" rating on the stock in a research note on Thursday, February 20th. StockNews.com lowered shares of Amicus Therapeutics from a "buy" rating to a "hold" rating in a research note on Thursday, February 20th. Finally, Needham & Company LLC restated a "hold" rating on shares of Amicus Therapeutics in a research note on Thursday, February 20th. Three analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $16.75.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.